{"organizations": [], "uuid": "2adb9ea659ecde527247e3e8d82e4df6835ee661", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-intercept-pharmaceuticals-says-201/brief-intercept-pharmaceuticals-says-2018-worldwide-ocaliva-net-sales-currently-expected-to-be-between-170-mln-185-mln-idUSASC0A0F3", "country": "US", "domain_rank": 408, "title": "BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.345, "site_type": "news", "published": "2018-05-08T19:25:00.000+03:00", "replies_count": 0, "uuid": "2adb9ea659ecde527247e3e8d82e4df6835ee661"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-intercept-pharmaceuticals-says-201/brief-intercept-pharmaceuticals-says-2018-worldwide-ocaliva-net-sales-currently-expected-to-be-between-170-mln-185-mln-idUSASC0A0F3", "ord_in_thread": 0, "title": "BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "intercept pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Intercept Pharmaceuticals Inc:\n* INTERCEPT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS, ISSUES 2018 OCALIVA NET SALES GUIDANCE AND PROVIDES BUSINESS UPDATE\n* Q1 REVENUE $36 MILLION VERSUS I/B/E/S VIEW $38.2 MILLION * 2018 WORLDWIDE OCALIVA NET SALES CURRENTLY EXPECTED TO BE BETWEEN $170 MILLION AND $185 MILLION\n* INTERCEPT - CONFIRMING PREVIOUSLY ANNOUNCED 2018 NON-GAAP ADJUSTED. OPERATING. EXPENSES GUIDANCE RANGE OF BETWEEN $390 MILLION AND $410 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T19:25:00.000+03:00", "crawled": "2018-05-09T12:36:30.019+03:00", "highlightTitle": ""}